Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491001 | 0.87 | PDE3B (0.47) | PDE3BPDE3AP2RY12MAPTALDH1A1 | |
| SCHEMBL2490558 | 0.85 | STING1 (0.36) | ALDH1A1LMNAKDM4EPOLBTDP1 | |
| SCHEMBL3417582 | 0.82 | MAPT (0.38) | DYRK1AMAPTALDH1A1LMNAHTT | |
| SCHEMBL13008103 | 0.82 | DYRK1A (0.37) | DYRK1APDE3BPDE3AP2RY12MAPT | |
| SCHEMBL526584 | 0.82 | LTA4H (0.52) | PDE3BPDE3AP2RY12MAPTALDH1A1 | |
| SCHEMBL525626 | 0.81 | PDE3B (0.34) | DYRK1APDE3BPDE3AP2RY12ALDH1A1 | |
| SCHEMBL14973527 | 0.81 | PDE3B (0.38) | DYRK1APDE3BPDE3AP2RY12PDE2A | |
| SCHEMBL12545033 | 0.76 | CNR1 (0.34) | MAPTALDH1A1KMT2AKDM4EHPGD | |
| SCHEMBL2610805 | 0.75 | NCF1 (0.38) | MAPTLMNAKDM4ETDP1SMN1; SMN2 | |
| SCHEMBL2610811 | 0.75 | NCF1 (0.38) | MAPTLMNAKDM4ETDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404678-B2 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| US-8404678-B2 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| US-8404678-B2 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| EP-2170890-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2011-10-26 | — | — | EP | disclosed |
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| EP-2170890-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009016516-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016516-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | TOMM34, TOMM70, TOMM40 | DYRK1A 3660/4885PDE3B 4130/4885PDE3A 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.